D-dimer Testing Market By Test Type (Laboratory Tests, Point-of-Care Tests), By Application (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Disseminated Intravascular Coagulation (DIC), Others), By End-use (Hospitals, Academic and Research Institutes, Diagnostic Centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
The global D-dimer testing market is anticipated to reach $2,166.5 million by 2032, growing from $1,318.7 million in 2022 at a CAGR of 5.1% from 2023 to 2032.
D-dimer testing stands as an advancement in evaluating coagulation irregularities, notably in scenarios of thromboembolic occurrences such as deep vein thrombosis (DVT) and pulmonary embolism (PE). This fibrin degradation product acts as a pivotal biomarker, indicative of ongoing fibrinolysis and clot formation. Globally, D-dimer assays are extensively utilized owing to their high sensitivity and specificity in diagnosing thrombotic ailments. Their significance is particularly known in emergency settings where swift diagnosis is paramount for timely intervention. Moreover, with the emergence of point-of-care testing, D-dimer assays have witnessed increased accessibility, facilitating prompt and effective screening of patients suspected of thromboembolic events. Consequently, ongoing global endeavors aim to refine D-dimer testing methodologies and standardize interpretation criteria, aiming to bolster diagnostic precision and enhance patient outcomes in the management of thrombotic disorders.
The urgency of early detection in thrombotic disorders and pulmonary embolism cannot be overstated. Efforts to raise awareness among healthcare professionals and the population play a pivotal role in prevention and timely intervention. The differentiating factor for D-dimer testing is its critical tool in identifying thrombotic conditions by detecting blood degradation products. Medical practitioners, through emphasizing the significance of D-dimer tests, expedite diagnosis and prompt initiation of appropriate treatments. Collaborative campaigns involving healthcare organizations, advocacy groups, and educational institutions are taking advantage of early detection of diseases, ultimately saving lives and reducing the burden of thrombotic disorders. Through targeted outreach and comprehensive education initiatives, the adoption of D-dimer testing is increased, ensuring that more individuals receive timely medical attention and interventions, thereby mitigating the risks associated with pulmonary embolism and thrombosis.
The widespread adoption of D-dimer testing, particularly in point-of-care settings, encounters significant challenges due to cost considerations. The expense associated with these tests, particularly in decentralized settings, acts as a barrier to broader implementation. Point-of-care testing offers rapid diagnosis and treatment decisions but often requires costly equipment and reagents, straining healthcare budgets. Consequently, affordability and availability issues limit D-dimer testing's integration into routine clinical practice. Addressing these cost-related challenges is crucial to ensure equitable access to D-dimer testing, especially in resource-constrained healthcare settings. Maximizing its potential for timely diagnosis and management of thrombotic disorders hinges on overcoming these financial obstacles.
The increasing focus on preventive care and early diagnosis, healthcare systems worldwide are witnessing a rise in demand for D-dimer testing. This test, crucial in detecting blood clotting disorders, is becoming a foundation in preemptive healthcare strategies. The global D-dimer testing market is experiencing rapid expansion, driven by a collective acknowledgment of its crucial role in averting serious health complications. By identifying potential clotting abnormalities proactively, healthcare providers can swiftly intervene, thus reducing risks and enhancing patient outcomes. This momentum signifies a paradigm shift towards proactive healthcare approaches, placing greater emphasis on wellness and preemptive actions over reactive treatments. As this trend gains momentum across healthcare landscapes globally, the D-dimer testing market is positioned to capitalize on the growing emphasis on early detection and intervention, thereby significantly contributing to the advancement of public health initiatives.
The key players profiled in this report include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Siemen Healthineers, Abbott, Biomerieux SA, WERFEN, HORIBA, Ltd., Quidel Corporation, Diazyme Laboratories, Inc., and Sekisui Diagnostics. The market players are continuously striving to achieve a dominant position in this competitive market using strategies such as collaborations and product launches.
Key Benefits for Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the d-dimer testing market analysis from 2022 to 2032 to identify the prevailing d-dimer testing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the d-dimer testing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global d-dimer testing market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Application
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Disseminated Intravascular Coagulation (DIC)
Others
By End-use
Hospitals
Academic and Research Institutes
Diagnostic Centers
Others
By Test Type
Point-of-Care Tests
Laboratory Tests
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
UAE
South Africa
Rest of LAMEA
Key Market Players
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche Ltd.
Siemen Healthineers
Abbott
biomerieux SA
WERFEN
Horiba Ltd
Quidel Corporation
Diazyme Laboratories, Inc.
Sekisui Diagnostics
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
- CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO perspective
- CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter’s five forces analysis
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
- 3.5. Average Selling Price
- 3.6. Market Share Analysis
- 3.7. Brand Share Analysis
- 3.8. Value Chain Analysis
- 3.9. Key Players Details
- 3.10. Key Regulation Analysis
- 3.11. Regulatory Guidelines
- 3.12. Patent Landscape
- CHAPTER 4: D-DIMER TESTING MARKET, BY TEST TYPE
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Laboratory Tests
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Point-of-Care Tests
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- CHAPTER 5: D-DIMER TESTING MARKET, BY APPLICATION
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Deep Vein Thrombosis (DVT)
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Pulmonary Embolism (PE)
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.4. Disseminated Intravascular Coagulation (DIC)
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
- 5.5. Others
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
- CHAPTER 6: D-DIMER TESTING MARKET, BY END-USE
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Academic and Research Institutes
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Diagnostic Centers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- 6.5. Others
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by region
- 6.5.3. Market share analysis by country
- CHAPTER 7: D-DIMER TESTING MARKET, BY REGION
- 7.1. Overview
- 7.1.1. Market size and forecast By Region
- 7.2. North America
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by Test Type
- 7.2.3. Market size and forecast, by Application
- 7.2.4. Market size and forecast, by End-use
- 7.2.5. Market size and forecast, by country
- 7.2.5.1. U.S.
- 7.2.5.1.1. Market size and forecast, by Test Type
- 7.2.5.1.2. Market size and forecast, by Application
- 7.2.5.1.3. Market size and forecast, by End-use
- 7.2.5.2. Canada
- 7.2.5.2.1. Market size and forecast, by Test Type
- 7.2.5.2.2. Market size and forecast, by Application
- 7.2.5.2.3. Market size and forecast, by End-use
- 7.2.5.3. Mexico
- 7.2.5.3.1. Market size and forecast, by Test Type
- 7.2.5.3.2. Market size and forecast, by Application
- 7.2.5.3.3. Market size and forecast, by End-use
- 7.3. Europe
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by Test Type
- 7.3.3. Market size and forecast, by Application
- 7.3.4. Market size and forecast, by End-use
- 7.3.5. Market size and forecast, by country
- 7.3.5.1. Germany
- 7.3.5.1.1. Market size and forecast, by Test Type
- 7.3.5.1.2. Market size and forecast, by Application
- 7.3.5.1.3. Market size and forecast, by End-use
- 7.3.5.2. UK
- 7.3.5.2.1. Market size and forecast, by Test Type
- 7.3.5.2.2. Market size and forecast, by Application
- 7.3.5.2.3. Market size and forecast, by End-use
- 7.3.5.3. France
- 7.3.5.3.1. Market size and forecast, by Test Type
- 7.3.5.3.2. Market size and forecast, by Application
- 7.3.5.3.3. Market size and forecast, by End-use
- 7.3.5.4. Spain
- 7.3.5.4.1. Market size and forecast, by Test Type
- 7.3.5.4.2. Market size and forecast, by Application
- 7.3.5.4.3. Market size and forecast, by End-use
- 7.3.5.5. Italy
- 7.3.5.5.1. Market size and forecast, by Test Type
- 7.3.5.5.2. Market size and forecast, by Application
- 7.3.5.5.3. Market size and forecast, by End-use
- 7.3.5.6. Rest of Europe
- 7.3.5.6.1. Market size and forecast, by Test Type
- 7.3.5.6.2. Market size and forecast, by Application
- 7.3.5.6.3. Market size and forecast, by End-use
- 7.4. Asia-Pacific
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by Test Type
- 7.4.3. Market size and forecast, by Application
- 7.4.4. Market size and forecast, by End-use
- 7.4.5. Market size and forecast, by country
- 7.4.5.1. China
- 7.4.5.1.1. Market size and forecast, by Test Type
- 7.4.5.1.2. Market size and forecast, by Application
- 7.4.5.1.3. Market size and forecast, by End-use
- 7.4.5.2. Japan
- 7.4.5.2.1. Market size and forecast, by Test Type
- 7.4.5.2.2. Market size and forecast, by Application
- 7.4.5.2.3. Market size and forecast, by End-use
- 7.4.5.3. India
- 7.4.5.3.1. Market size and forecast, by Test Type
- 7.4.5.3.2. Market size and forecast, by Application
- 7.4.5.3.3. Market size and forecast, by End-use
- 7.4.5.4. South Korea
- 7.4.5.4.1. Market size and forecast, by Test Type
- 7.4.5.4.2. Market size and forecast, by Application
- 7.4.5.4.3. Market size and forecast, by End-use
- 7.4.5.5. Australia
- 7.4.5.5.1. Market size and forecast, by Test Type
- 7.4.5.5.2. Market size and forecast, by Application
- 7.4.5.5.3. Market size and forecast, by End-use
- 7.4.5.6. Rest of Asia-Pacific
- 7.4.5.6.1. Market size and forecast, by Test Type
- 7.4.5.6.2. Market size and forecast, by Application
- 7.4.5.6.3. Market size and forecast, by End-use
- 7.5. LAMEA
- 7.5.1. Key market trends, growth factors and opportunities
- 7.5.2. Market size and forecast, by Test Type
- 7.5.3. Market size and forecast, by Application
- 7.5.4. Market size and forecast, by End-use
- 7.5.5. Market size and forecast, by country
- 7.5.5.1. Brazil
- 7.5.5.1.1. Market size and forecast, by Test Type
- 7.5.5.1.2. Market size and forecast, by Application
- 7.5.5.1.3. Market size and forecast, by End-use
- 7.5.5.2. Saudi Arabia
- 7.5.5.2.1. Market size and forecast, by Test Type
- 7.5.5.2.2. Market size and forecast, by Application
- 7.5.5.2.3. Market size and forecast, by End-use
- 7.5.5.3. UAE
- 7.5.5.3.1. Market size and forecast, by Test Type
- 7.5.5.3.2. Market size and forecast, by Application
- 7.5.5.3.3. Market size and forecast, by End-use
- 7.5.5.4. South Africa
- 7.5.5.4.1. Market size and forecast, by Test Type
- 7.5.5.4.2. Market size and forecast, by Application
- 7.5.5.4.3. Market size and forecast, by End-use
- 7.5.5.5. Rest of LAMEA
- 7.5.5.5.1. Market size and forecast, by Test Type
- 7.5.5.5.2. Market size and forecast, by Application
- 7.5.5.5.3. Market size and forecast, by End-use
- CHAPTER 8: COMPETITIVE LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product mapping of top 10 player
- 8.4. Competitive dashboard
- 8.5. Competitive heatmap
- 8.6. Top player positioning, 2022
- CHAPTER 9: COMPANY PROFILES
- 9.1. Thermo Fisher Scientific Inc.
- 9.1.1. Company overview
- 9.1.2. Key executives
- 9.1.3. Company snapshot
- 9.2. F. Hoffmann-La Roche Ltd.
- 9.2.1. Company overview
- 9.2.2. Key executives
- 9.2.3. Company snapshot
- 9.3. Siemen Healthineers
- 9.3.1. Company overview
- 9.3.2. Key executives
- 9.3.3. Company snapshot
- 9.4. Abbott
- 9.4.1. Company overview
- 9.4.2. Key executives
- 9.4.3. Company snapshot
- 9.5. biomerieux SA
- 9.5.1. Company overview
- 9.5.2. Key executives
- 9.5.3. Company snapshot
- 9.6. WERFEN
- 9.6.1. Company overview
- 9.6.2. Key executives
- 9.6.3. Company snapshot
- 9.7. Horiba Ltd
- 9.7.1. Company overview
- 9.7.2. Key executives
- 9.7.3. Company snapshot
- 9.8. Quidel Corporation
- 9.8.1. Company overview
- 9.8.2. Key executives
- 9.8.3. Company snapshot
- 9.9. Diazyme Laboratories, Inc.
- 9.9.1. Company overview
- 9.9.2. Key executives
- 9.9.3. Company snapshot
- 9.10. Sekisui Diagnostics
- 9.10.1. Company overview
- 9.10.2. Key executives
- 9.10.3. Company snapshot
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook